Senti Biosciences Inc.

12/02/2024 | Press release | Distributed by Public on 12/02/2024 06:46

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI 202, a Logic Gated, Selective CD33/FLT3 Targeting CAR NK Cell Therapy for the Treatment of[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.